Home > Boards > US OTC > Biotechs >

Amarantus Bioscience Holdings Inc. (AMBSD)

Add AMBSD Price Alert      Hide Sticky   Hide Intro
Moderator: No Moderator 1-eye-jack, joboggi, zoomboom, JJAAMMAANN, Rosym
Search This Board:
Last Post: 7/3/2015 10:41:19 PM - Followers: 725 - Board type: Free - Posts Today: 0


(AMBS) Amarantus BioScience Holdings, Inc.

Amarantus is a biotechnology company developing treatments and diagnostics for diseases associated with neurodegeneration and protein misfolding-related apoptosis.
The company has licensed Eltoprazine, a Phase 2B ready Parkinsons Levadopa induced Dyskinesia.

The company has an exclusive worldwide license to the Lymphocyte Proliferation test ("LymPro Test®") is a
 diagnostic blood test for Alzheimer’s disease and is being evaluated as a diagnostic blood test for Traumatic Brain injury and Chronic Traumatic Encephalopathy.  (MANF) is a human growth factor that plays a key role in the prevention of apoptosis (cell death). It is being developed for the potential treatment of RP, Parkinson's disease, Wolfram syndrome, diabetes, Alzheimer's disease and traumatic brain injury.
Amarantus is a Founding Member of the Coalition for Concussion Treatment (#C4CT), a movement initiated in collaboration with Brewer Sports International seeking to raise awareness of new treatments in development for concussions and nervous-system disorders.
The Company also owns intellectual property rights for the diagnosis of Parkinson's Disease ("NuroPro") and the discovery of neurotrophic facotrs ("PhenoGuard").

ESS, previously known as PermaDerm®  is being developed to be the only tissue-engineered skin prepared from autologous (patient's own) skin cells consisting of both epidermal and dermal layers. A small harvested section of the patient's own skin can be grown to graft an area one hundred times its size in as little as thirty days. 

MSPrecise is a groundbreaking advancement for the diagnosis of multiple sclerosis and is anticipated to play a pivotal role given the current high rate of misdiagnosis
MSPrecise is a lab-developed test, and the successful completion of the validation study paves the way for this clinically important test to be commercialized in 2015. 
For further information, please visit, or connect with the company in FacebookTwitter, LinkedIn & Google+





Amarantus Announces Issuance of United States Patent No. 9,066,903 Covering Proprietary Methods of Administration of Eltoprazine for the Treatment of Parkinson's Disease  -  Patent Provides IP Protection for Lead Product Candidate Eltoprazine for the Treatment of Parkinson's Disease    -   June 30, 2015
Amarantus Sets Sights On NASDAQ
Jason Napodano, CFA   -   May 29, 2015  

Amarantus Enters Into CRO Agreement With Chiltern International to Commence Phase 2b Clinical Development of Eltoprazine in Parkinson's Disease Levodopa-Induced Dyskinesia - Company Completes Investigator Meetings in U.S. and E.U. in Preparation for Study Launch -  Enrollment and Dosing for 60-Patient PD-LID Study on Track to Commence 2Q 2015 
May 21, 2015
Amarantus Reports First Quarter 2015 Financial Results and Business Overview  - Eltoprazine Phase 2b clinical program on track to commence in 2Q 2015 -     
May 20, 2015   
Amarantus Announces Successful Delivery and Distribution of MANF in Preclinical Model to Brain Areas Involved in Parkinson's Disease - Demonstrated MANF Can be Precisely Delivered to Parkinson's-Associated Brain Areas.
May 15, 2015
MANF Begins its March Towards the Clinic
May 14th, 2015

Amarantus Enters Into cGMP Manufacturing Agreement With Catalent Biologics for Production of MANF for Human Clinical Studies
May 14, 2015
Amarantus Receives Notice of Allowance for U.S. Patent Application Covering Proprietary Methods of Administration and Compositions in the Treatment of Parkinson's Disease  -  Patent Issuance Will Provide IP Protection for Lead Product Candidate Eltoprazine for Treatment of Parkinson's Disease Levodopa-Induced Dyskinesia (PD-LID)
May 13, 2015
Amarantus Announces the Presentation of Data Showing MANF's Positive Effect on Retinal Function at Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting
May 7, 2015 
Amarantus Receives Notice of Allowance for U.S. Patent Application Covering Proprietary Compositions of Matter and Methods of Use for MANF
May 5, 2015
Amarantus Granted European Union Orphan Drug Designation for MANF for the Treatment of Retinitis Pigmentosa
April 29, 2015

Developing clinical-stage products in neurology, psychiatry and orphan indications BUSINESS UPDATE CONFERENCE CALL April 9, 2015
April 9, 2015
Amarantus Reports 2014 Financial Results and Business Overview - 
 First pharmaceutical customer in the first quarter of 2015, garnered its first pharmaceutical customer in the first quarter of 2015, as the interest in trials of experimental Alzheimer's therapies is beginning to increase with high-profile successes renewing hope for the field.
April 7, 2015
A Deep Look At Amarantus’ Phase 2b Eltoprazine For Parkinson’s Dyskinesia
By Jason NapodanoWednesday, March 4, 2015
Amarantus Announces Publication in BRAIN of Eltoprazine Phase 2a Clinical Study for Treating Parkinson's Disease Levodopa-Induced Dyskinesia - The study was partially supported by a grant from Michael J. Fox Foundation for Parkinson's Research.
Feb. 10, 2015
Congressman Fattah Meets with Biotech Company on Brain Research Efforts; Announced as Co-Chair of Alzheimer`s Caucus
February 03/15
Amarantus Announces Exclusive Option Agreement With Georgetown University to License Patent Rights for Blood Based Biomarkers for Alzheimer's Disease
Jan. 15, 2015
More News


Predicting Alzheimer's before it starts
Published on Apr. 8, 2015

Developing an Accurate Test for Multiple Sclerosis
Mar. 5, 2014

SNNLive - Amarantus BioScience Holdings, Inc
Dec. 12, 2014

Amarantus BioScience
Oct. 19, 2014





Company Information

Investor Relations

Transfer Agent

Amarantus BioScience Holdings, Inc.
c/o Janssen Labs @ QB3
953 Indiana Street
San Francisco, CA 94107

c/o ICS Corporate Services SA
29 quai du Mont Blanc
CH-1201 Geneva

Phone: (408) 737-2734
Fax: (408) 852-4427

Aimee Boutcher
Director of Investor Relations
Amarantus BioScience Holdings, Inc

408-737-2734 x101

Gerald's email address

IR Calendar 
Upcoming Events
VStock Transfer, LLC
77 Spruce Street, Suite 201
Cedarhurst, NY 11516

Attn: Allison Niccols

Phone: 212-828-8436
Toll-Free: 855-9VSTOCK
Fax: 646-536-3179 

Throughout my 50+ years in the biopharmaceutical industry, I have seen many programs with great promise, but very few programs that possess the fundamentally groundbreaking scientific potential to modify disease biology inherent in MANF This vast potential for MANF is what makes today’s announcement personally so exciting for me, as the initiation of IND-enabling studies (which start with initiation of clinical grade manufacturing) has been the rate-limiting step for true product development value creation for MANF not only for the ophthalmology programs, but also the rest of the MANF pipeline.

  Dr. Wen commented, "We continue to see very encouraging preclinical data with MANF. I am looking forward to continue further development of MANF in collaboration with Amarantus, as I believe it has the potential to address RP, as well as other ophthalmologic disorders with serious unmet need and improve the quality of life of patients where no viable treatments exist today."
More information
         “We are very pleased with the data generated in RP from Dr. Wen’s lab at University of Miami’s Bascom Palmer Eye Institute, one of the world’s most prestigious ophthalmology research and treatment centers,” said Gerald E. Commissiong, President & CEO of Amarantus BioScience Holdings, Inc. “Given the recent granting of orphan drug designations in both the US and EU, the presentation of this data is very timely as we build momentum for MANF in this devastating orphan indication, as well as continue to further establish the MANF orphan ophthalmology franchise.

   Amarantus Receives Orphan Drug Designation for MANF From U.S. Food and Drug Administration for Treatment of Retinitis Pigmentosa
 "We are very pleased to receive orphan drug designation for MANF in RP. This represents an important milestone for the company as well as a significant step forward for our clinical and regulatory strategy," said Gerald E. Commissiong
 Most people with RP are legally blind by age 40. It is estimated that the market opportunity for Retinitis Pigmentosa exceeds $10B annually.

        smiley    BUSINESS UPDATE CONFERENCE CALL - Presentation (PDF)  May 27, 2015   yes
       Amarantus BioScience's (AMBS) CEO Gerald Commissiong Hosts Business Update Conference Call (Transcript)

                 SeeThru Equity 4th Annual Microcap Investor Conference - Webcast 
Bio International Convention Conference - Live Webcast  June 16, 2015 - Huge Biotechnology Convention Opens in Philadelphia

                           2 Conferences
•  Alzheimer's Association International Conference  AAIC>.15   -  July 18-23, 2015,    Washington, D.C. United States
UN Brain Health Summoit - United Nations, NYC - July 22, 2015  

  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
Current Price
Bid Ask Day's Range
AMBS News: Amarantus to Present at the BIO International Convention 06/10/2015 08:05:00 AM
AMBS News: Current Report Filing (8-k) 06/09/2015 05:17:35 PM
AMBS News: Amarantus Completes Capital Restructuring in Preparation for National Exchange Listing 06/09/2015 04:05:00 PM
AMBS News: Current Report Filing (8-k) 06/09/2015 12:08:08 PM
AMBS News: Amarantus Diagnostics Announces Acceptance of Two Late-Breaking Abstracts on LymPro Test(R) Data at the 2015 Alzheimer's Asso... 06/09/2015 10:58:03 AM
#113003  Sticky Note From the new Zack's Research Report(Apr '15) "AMBS cjstocksup 04/29/15 04:15:17 PM
#110746  Sticky Note Jason Napodano - 15 Biotech Names For 2015 Rosym 01/05/15 04:13:55 PM
#104968  Sticky Note MJFF is firm with their notion that NFs joboggi 07/17/14 02:01:07 AM
#115691   3 Milestones to ASMBS Uplisting JPetroInc 07/03/15 10:41:19 PM
#115690   Oh...he knows...and he's a shareholder as well. lighter than AIR 07/03/15 07:34:41 PM
#115689   Then stop posting on this board, loser!! Mdiaz 07/03/15 06:29:28 PM
#115688   listen man...this company has issued NOTHING of importance Alapis 07/03/15 12:40:15 PM
#115687   you are correct BR JPetroInc 07/03/15 12:16:44 PM
#115686   Hey JP - since the market it closed brharris 07/03/15 11:09:34 AM
#115685   Pathetic whiners Companies don't issue major headline every day jeffshir 07/03/15 10:42:37 AM
#115684   So, when we do the -- after we’ve JPetroInc 07/02/15 11:18:21 PM
#115683   Nothing has changed since the conference call: brharris 07/02/15 09:37:57 PM
#115682   what's the latest on the nasdaq uplisting anyone? IPO$ 07/02/15 01:31:28 PM
#115681   i'm wondering if his family is aware of Alapis 07/02/15 01:25:56 PM
#115679   The only problem with $4 is that it joboggi 07/02/15 12:27:00 PM
#115677   something has to happen ????!!!!!! ron51 07/02/15 10:51:32 AM
#115676   look at the volume...Gerry really has ZERO understanding Alapis 07/02/15 09:48:27 AM
#115675   GC is fooling his fellow shareholders since more Alapis 07/02/15 09:04:45 AM
#115674   what really pisses me off is that GC Alapis 07/02/15 08:29:47 AM
#115673   above $ 4 which is not a problem Alapis 07/02/15 08:18:12 AM
#115672   nope they need at least $ 4 mil in der_deutschetrader 07/02/15 08:12:33 AM
#115671   That is not an automatic calendar event, does Ragnaroc 07/02/15 08:12:00 AM
#115670   14 more trading days left until they meet Alapis 07/02/15 07:56:01 AM
#115669   well this is Gerry...he thinks it's important....he is Alapis 07/02/15 07:47:27 AM
#115668   the patent belongs to the Veteran's Admin der_deutschetrader 07/02/15 07:46:20 AM
#115666 der_deutschetrader 07/02/15 07:42:24 AM
#115665   patent was issued to the Veteran's Admin der_deutschetrader 07/02/15 07:41:31 AM
#115664   nor did I read anything in the PR JPetroInc 07/02/15 07:19:22 AM
#115663   Good point and I believe you are correct. brharris 07/01/15 11:12:05 PM
#115662   Agreed it does help. Allows them access to brharris 07/01/15 11:09:05 PM
#115661   There is one caveat though if the product GS1 07/01/15 11:08:42 PM
#115660   This new issuance helps the Company continue to JPetroInc 07/01/15 11:03:21 PM
#115659   In general you are correct about how patents brharris 07/01/15 10:57:59 PM
#115658   Then question is who owns the patent for GS1 07/01/15 10:49:21 PM
#115657   But doesn't say issued to AMBS. The patent brharris 07/01/15 10:31:05 PM
#115656   The company said patent has been issued.. GS1 07/01/15 10:23:29 PM
#115655   After re-reading the PR from AMBS they didn't brharris 07/01/15 10:08:07 PM
#115654   The USPTO database doesn't show up any name GS1 07/01/15 07:06:47 PM
#115653   Gerry's definition of "shortly" is somehow new....shortly means Alapis 07/01/15 06:34:13 PM
#115652   Institutional MMs? Some hedge funds are shorting biotech BBalls-N-CowTown 07/01/15 05:06:34 PM
#115650   Flippers getting out cause this going to run soon myersvodka 07/01/15 04:45:40 PM
#115649   Gerals is a little baby who has NOW Alapis 07/01/15 03:07:11 PM
#115648   5.94 x 5.95 JPetroInc 07/01/15 02:49:31 PM
#115647   The shareprice and the volume speaks for itself! sante1 07/01/15 01:50:47 PM
#115646   CDEL CANT CSTI all on the ASK JPetroInc 07/01/15 01:22:13 PM
#115645   Working both sides now, number 1 on the brharris 07/01/15 12:56:30 PM
#115643   CANT - relentless on the ASK JPetroInc 07/01/15 12:03:16 PM
#115642   Don't be so sure of an uplist until SidVicious 07/01/15 11:22:03 AM
#115640   5.95 / 6.03 JPetroInc 07/01/15 11:11:01 AM
#115639   Yes, sounds good! Rosym 07/01/15 10:49:12 AM
#115638   soonest would be 7/21 to uplist JPetroInc 07/01/15 10:41:14 AM
#115637   I think it will be near the end Rosym 07/01/15 10:37:51 AM
#115636   Do we know the date of the formal myersvodka 07/01/15 10:24:20 AM